Physician profile
Peter Mattei
NPI 1013195759
$2,404.72
in general payments reported to CMS, 2019-2025
17 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,539 · 2020: $541 · 2021: $101 · 2023: $60.00 · 2024: $42.00 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $125.35 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $708.02 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $307.41 | 2019-2020 | |
| Abbvie INC. | $296.30 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $240.20 | 2019-2020 | |
| Pfizer INC. | $181.49 | 2019-2023 | |
| Almirall LLC | $158.50 | 2019 | |
| Eli Lilly and Company | $99.00 | 2025 | |
| Janssen Scientific Affairs, LLC | $96.24 | 2019 | |
| Janssen Biotech, INC. | $94.72 | 2019-2021 | |
| Leo Pharma INC. | $50.33 | 2019-2021 | |
| Biofrontera INC. | $42.00 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Mayne Pharma Commercial LLC | $33.26 | 2019 | |
| Alexion Pharmaceuticals, INC. | $23.35 | 2025 | Ultomiris |
| Incyte Corporation | $20.91 | 2021 | |
| Vyne Pharmaceuticals INC. | $20.44 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $19.55 | 2020 | |
| Glenmark Therapeutics INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Mattei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.